References
- Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, et al. The global burden of cancer 2013. JAMA Oncol [ Internet] 2015;1:505–527. [Accessed 2015 Jul 29]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4500822&tool=pmcentrez&rendertype=abstract.
- Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer [ Internet] 2002;2:342–350. [Accessed 2014 Jul 17]. http://www.ncbi.nlm.nih.gov/pubmed/12044010.
- Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol [ Internet] 2002;55:244–265. [Accessed 2015 Feb 25]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1769629&tool=pmcentrez&rendertype=abstract.
- Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer [ Internet] 2005;15:727–746. [Accessed 2015 Oct 4]. http://www.ncbi.nlm.nih.gov/pubmed/16174218.
- Brinkman JA, Hughes SH, Stone P, Caffrey AS, Muderspach LI, Roman LD, Weber JS, Kast WM. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers [ Internet] 2007;23:337–352. [Accessed 2015 Oct 4]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3851105&tool=pmcentrez&rendertype=abstract.
- Daemen T, Regts J, Holtrop M, Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther [ Internet] 2002;9:85–94. [Accessed 2015 Aug 17]. http://www.ncbi.nlm.nih.gov/pubmed/11857066.
- Daemen T, Riezebos-Brilman A, Regts J, Dontje B, Van Der Zee A, Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther. 2004;9:733–742. https://www.ncbi.nlm.nih.gov/pubmed/15535411
- Näslund TI, Kostic L, Nordström EKL, Chen M, Liljeström P. Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol J. 2011;8:36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038947/
- Ljungberg K, Liljeström P. Self-replicating alphavirus RNA vaccines. Expert Rev Vaccines [ Internet] 2015;14:177–194. [Accessed 2015 Sep 27]. http://www.ncbi.nlm.nih.gov/pubmed/25269775.
- Chen M, Barnfield C, Näslund TI, Fleeton MN, Liljeström P. MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells. J Virol [ Internet] 2005;79:2964–2972. [Accessed 2015 Dec 6]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=548467&tool=pmcentrez&rendertype=abstract.
- Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, Alexopoulou L, Azuma Y-T, Flavell RA, Liljeström P, Reis E Sousa C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature [ Internet] 2005;433:887–892. [Accessed 2017 Apr 11]. http://www.nature.com/doifinder/10.1038/nature03326.
- Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet [ Internet] 2008;9:776–788. [Accessed 2015 Oct 27]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4317294&tool=pmcentrez&rendertype=abstract.
- van de Wall S, Nijman HW, Daemen T. HPV-specific immunotherapy: key role for immunomodulators. Anticancer Agents Med Chem [ Internet] 2014;14:265–279. http://www.ncbi.nlm.nih.gov/pubmed/24237218.
- Lee S-H, Danishmalik SN, Sin J-I. DNA Vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother [ Internet] 2015. http://www.tandfonline.com/doi/full/10.1080/21645515.2015.1035502.
- Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res [ Internet] 2008;42:219–232. [Accessed 2015 Dec 6]. http://www.ncbi.nlm.nih.gov/pubmed/19066740.
- van de Wall S, Walczak M, Van Rooij N, Hoogeboom B-N, Meijerhof T, Nijman H, Daemen T. Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7. Vaccines [ Internet] 2015;3:221–238. [Accessed 2015 Aug 7]. http://www.mdpi.com/2076-393X/3/2/221/htm.
- Kis EE, Winter G, Myschik J. Devices for intradermal vaccination. Vaccine. 2012;30:523–538. doi:10.1016/j.vaccine.2011.11.020.
- Knudsen ML, Mbewe-Mvula A, Rosario M, Johansson DX, Kakoulidou M, Bridgeman A, Reyes-Sandoval A, Nicosia A, Ljungberg K, Hanke T, et al. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. J Virol [ Internet] 2012;86:4082–4090. [Accessed 2015 Jul 13]. http://jvi.asm.org/content/86/8/4082.long.
- Knudsen ML, Ljungberg K, Tatoud R, Weber J, Esteban M, Liljeström P. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen. PLoS One [ Internet] 2015;10:e0117042. [Accessed 2016 Feb 7]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4314072&tool=pmcentrez&rendertype=abstract.
- Yamanaka R, Xanthopoulos KG. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18. DNA Cell Biol [ Internet] 2005;24:317–324. [Accessed 2015 Dec 6]. http://www.ncbi.nlm.nih.gov/pubmed/15869409.
- Leslie MC, Zhao Y-J, Lachman LB, Hwu P, Wu G-J, Bar-Eli M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther [ Internet] 2007;14:316–323. [Accessed 2016 Feb 7]. http://www.ncbi.nlm.nih.gov/pubmed/17024104.
- Ohlschläger P, Pes M, Osen W, Dürst M, Schneider A, Gissmann L, Kaufmann AM. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine [ Internet] 2006;24:2880–2893. [Accessed 2015 Aug 17]. http://www.ncbi.nlm.nih.gov/pubmed/16472545.
- Oosterhuis K, Aleyd E, Vrijland K, Schumacher TN, Haanen JB. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Hum Gene Ther. 2012;1312:121031083217002.
- Peng IP, Boerma A, Walczak M, Oosterhuis K, Haanen JB, Schumacher TN, Nijman HW, Daemen T. Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Ther [ Internet] 2015;560–567. http://www.nature.com/doifinder/10.1038/gt.2015.24.
- Knudsen ML, Ljungberg K, Kakoulidou M, Kostic L, Hallengärd D, García-Arriaza J, Merits A, Esteban M, Liljeström P. Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations. J Virol [ Internet] 2014;88:12438–12451. [Accessed 2015 Jan 14]. http://www.ncbi.nlm.nih.gov/pubmed/25122792.
- Nordström EKL, Forsell MNE, Barnfield C, Bonin E, Hanke T, Sundström M, Karlsson GB, Liljeström P. Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J Gen Virol [ Internet] 2005;86:349–354. [Accessed 2015 Jul 14]. http://www.ncbi.nlm.nih.gov/pubmed/15659754.
- Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine [ Internet] 1999;18:765–777. [Accessed 2015 Sep 27]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1986720&tool=pmcentrez&rendertype=abstract.
- Nikonov A, Mölder T, Sikut R, Kiiver K, Männik A, Toots U, Lulla A, Lulla V, Utt A, Merits A, et al. RIG-I and MDA-5 detection of viral RNA-dependent RNA polymerase activity restricts positive-strand RNA virus replication. PLoS Pathog [ Internet] 2013;9:e1003610. [Accessed 2016 Jun 21]. http://www.ncbi.nlm.nih.gov/pubmed/24039580.
- Diebold SS, Schulz O, Alexopoulou L, Leitner WW, Flavell RA, Reis E Sousa C. Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther [ Internet] 2009;16:359–366. [Accessed 2015 Jan 1]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2655288&tool=pmcentrez&rendertype=abstract.
- Glasgow GM, McGee MM, Sheahan BJ, Atkins GJ. Death mechanisms in cultured cells infected by Semliki Forest virus. J Gen Virol [ Internet] 1997;78(Pt 7):1559–1563.[Accessed 2016 Feb 7]. http://www.ncbi.nlm.nih.gov/pubmed/9225029.
- Best SR, Peng S, Juang C-M, Hung C-F, Hannaman D, Saunders JR, Wu T-C, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine [ Internet] 2009;27:5450–5459. [Accessed 2015 Aug 7]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2745985&tool=pmcentrez&rendertype=abstract.
- Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet (London, England) [ Internet] 2015. [Accessed 2015 Sep 22]. http://www.ncbi.nlm.nih.gov/pubmed/26386540.
- Oosterhuis K, Ohlschläger P, Van Den Berg JH, Toebes M, Gomez R, Schumacher TN, Haanen JB. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. Int J Cancer. 2011;129;397–406. doi:10.1002/ijc.25894.
- Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 2000;60:51–55.
- Ahrends T, Baba AN, Xiao Y, Yagita H, Van Eenennaam H, Borst J. CD27 agonism plus PD-1 blockade recapitulates CD4+ T cell help in therapeutic anti-cancer vaccination. Cancer Res [ Internet] 2016;1–12. http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-15-3130.
- Lambeck AJA, Nijman HW, Hoogeboom BN, Regts J, De Mare A, Wilschut J, Daemen T. Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine. 2010;28;4275–4282. doi:10.1016/j.vaccine.2010.04.033.
- Berglund P, Fleeton MN, Smerdou C, Liljeström P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine [ Internet] 1999;17:497–507. [Accessed 2016 Nov 15]. http://www.ncbi.nlm.nih.gov/pubmed/10073729.
- Uematsu Y, Vajdy M, Lian Y, Perri S, Greer CE, Legg HS, Galli G, Saletti G, Otten GR, Rappuoli R, et al. Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol [ Internet] 2012;19:991–998. [Accessed 2018 May 12]. http://cvi.asm.org/lookup/doi/10.1128/CVI.00031-12.
- Näslund TI, Uyttenhove C, Nordström EKL, Colau D, Warnier G, Jondal M, Van Den Eynde BJ, Liljeström P. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J Immunol [ Internet] 2007;178:6761–6769. [Accessed 2017 Apr 18]. http://www.ncbi.nlm.nih.gov/pubmed/17513723.
- Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev [ Internet] 2006;211:214–224. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1501075&tool=pmcentrez&rendertype=abstract.
- Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, et al. Central memory self͞tumor-reactive CD8 T cells confer superior antitumor immunity compared with effector memory T cells. 2005 [Accessed 2017 Apr 17]; http://www.pnas.org/content/102/27/9571.full.pdf
- Walczak M, De Mare A, Riezebos-Brilman A, Regts J, Hoogeboom B-N, Visser JT, Fiedler M, Jansen-Dürr P, Van Der Zee AGJ, Nijman HW, et al. Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine. Mol Pharm [ Internet] 2011;8:65–77. [Accessed 2017 Apr 11]. http://www.ncbi.nlm.nih.gov/pubmed/20825215.
- Peng S, Tomson TT, Trimble C, He L, Hung C-F, Wu T-C. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther [ Internet] 2006;13:257–265. [Accessed 2015 Aug 17]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2174916&tool=pmcentrez&rendertype=abstract.
- Piersma SJ, Jordanova ES, Van Poelgeest MIE, Kwappenberg KMC, Van Der Hulst JM, Drijfhout JW, Melief CJM, Kenter GG, Fleuren GJ, Offringa R, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res [ Internet] 2007;67:354–361. [Accessed 2015 Sep 30]. http://www.ncbi.nlm.nih.gov/pubmed/17210718.
- Smerdou C, Liljeström P. Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol [ Internet] 1999;73:1092–1098. [Accessed 2016 Nov 15]. http://www.ncbi.nlm.nih.gov/pubmed/9882310.